StockData
COONasdaqOphthalmic GoodsFiscal year ends October 31

COOPER COMPANIES, INC.

Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026
$58.16+0.22 (+0.38%)

Close on Oct 19, 2026

Market cap
$11.25B
P/E (TTM)
19.8
Dividend yield
–

COOPER COMPANIES, INC. revenue by segment

By business segment

RevenueFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016% of revenueYoY
Coopervision Segment$2.74B$2.61B$2.42B$2.24B$2.15B$1.84B$1.97B$1.88B$1.67B–67.0%+5.2%
CooperVision$2.74B$2.61B$2.42B$2.24B$2.15B–––––67.0%+5.2%
Coopersurgical Segment$1.35B$1.29B$1.17B$1.07B$770.50M$587.90M$680.50M$650.80M$464.90M–33.0%+4.9%
CooperSurgical$1.35B$1.29B$1.17B$1.07B$770.50M–––––33.0%+4.9%
CooperVision–––––––$1.88B$1.67B$1.58B––
CooperSurgical–––––––$650.80M$464.90M$389.60M––
Corporate–––––––$0$0$0––
Operating incomeFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016YoY
CooperVision$729.60M$676.20M$587.70M$494.30M$481.30M–––––+7.9%
CooperSurgical$43.40M$118.30M$16.10M$67.10M$71.80M–––––-63.3%
Coopervision Segment–––$494.30M$481.30M$375.70M$506.40M$479.80M$418.40M––
Coopersurgical Segment–––$67.10M$71.80M-$14.70M$87.90M-$19.90M$58.50M––
CooperVision–––––––$479.80M$418.40M$309.80M–
CooperSurgical–––––––-$19.90M$58.50M$60.20M–
Corporate–––––––-$56.80M-$47.80M-$45.90M–

By product or service

By region

RevenueFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016% of revenueYoY
United States$2.05B$1.97B$1.81B$1.64B$1.34B$1.10B$1.21B$1.16B$1.19B$1.14B50.2%+4.5%
Europe$1.25B$1.16B$1.04B$987.20M$957.90M$789.80M$854.80M$846.50M$1.19B$1.15B30.6%+8.4%
Rest of World$785.20M$773.60M$739.80M$682.70M$625.40M$537.50M$586.80M$524.10M––19.2%+1.5%
Rest of World, Other Eliminations & Corporate––––––-$364.70M-$157.30M-$234.50M-$319.60M––

From the segment and revenue-disaggregation notes of Cooper Companies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.